INVESTOR DECK

CONTENTS
3. Confidentiality & Disclaimer

4. Safe Harbor

5. Chemesis at a Glance

6. Our Strategy

7. California

13. Puerto Rico

15. Colombia

17. Projections

18. Cap Table

2
CONFIDENTIALITY & DISCLAIMER
This presentation has been prepared by Chemesis Inc. (the “Company”, or “Chemesis”) for
the purpose of conveying certain confidential information to you regarding our business.

References to the “presentation” include any written or oral information that has
been, or may be supplied to you by, or on behalf of the Company in connection with
this presentation including any further inquiries that you may make in respect to this
presentation. This presentation has been furnished to you on a confidential basis solely
for the purpose of enabling you to evaluate a potential investment in our Company.

This presentation and the information contained herein is confidential. Neither you nor your
employees, directors, agents, representatives or advisors may copy, reproduce or distribute this
presentation, in whole or in part, to anyone without the prior written consent of Biolab. By accepting
this presentation, you agree to keep confidential all information contained herein, and to use this
presentation for the sole purpose of evaluating our business. Chemesis shall not be liable for any
direct, indirect or consequential loss or damages suffered by you in reliance upon any information
contained in, or as a result of any omission of information from, this presentation or any other
information furnished to you in connection herewith, and any such liability is expressly disclaimed.

This presentation does not constitute an offer to sell any securities to, or a solicitation of an
offer to buy any securities from, any person in any state or other jurisdiction. Any offer or sale
of securities of will only be made pursuant to a mutually acceptable written securities.

3
SAFE HARBOR
This presentation contains forward-looking statements. With the exception of historical facts,
or those incorporated by reference, all statements within this presentation are forward-looking
statements. Forward-looking statements include, but are not limited to, all statements regarding
the future financial position, business strategy, budgets, projected revenue and costs, and plans
and objectives of management for future operations of Chemesis. In addition, forward-looking
statements can generally be identified by the use of terminology such as “may”, “will”, “expects”,
“intends”, “plans”, “projects”, “estimates”, “anticipates”, “believes”, as well as similar terminology
and expressions, or the negative variations thereof. The Company has based these forward-looking
statements on its current expectations and projections about future events. These forward-looking
statements are not guarantees, and are subject to known and unknown risks, uncertainties and
assumptions that may cause the actual results of Chemesis to differ materially from the proposed
results in such statements. Although Chemesis believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance that such expectations will
prove to have been correct. Important factors that could cause actual results to differ materially
from proposed expectations include, but are not limited to, the Company’s ability to fund its future
growth, implement its business strategy, obtain marijuana licenses from California, design, build and
operate processing facilities and dispensaries, and comply with applicable state and local laws and
regulations. All subsequent written and oral forward-looking statements attributable to Chemesis, or
persons acting on behalf are of Chemesis, expressly qualified in their entirety by the foregoing. Except
as required by law, Chemesis assumes no duty to update or revise its forward-looking statements.

4
CHEMESIS AT A GLANCE
Chemesis is an innovative, first-mover in the cannabis industry & will leverage it’s worldwide reach & exclusive partnerships by providing knowledge,
structure & confident leadership. Chemesis will grow new markets & revenues within cultivation, manufacturing, distribution, & retail sales.

STOCK TICKERS
• CSI (CSE)
• CADMF (OTC)
• CWAA (FRA)
Cultivation Manufacturing Distribution Retail Sales

5
OUR STRATEGY
Chemesis leverages long term relationships in key markets to grow its footprint in emerging markets. Chemesis strives to build consistent revenues that
create long-term growth, by maintaining cost effective and exclusive partnerships that allow for further market penetration.

CURRENT OPERATIONS MARKET EXPANSION

California, Puerto Rico, Colombia Europe, Australia, rest of the US, Latin America

6
CALIFORNIA / MARKET
Market size and potential in California.
Chemesis is able to provide a one
stop shop for brands that need fully
compliant manufacturing, packaging,
distribution, and transportation
services throughout the state.

CALIFORNIA UNITED STATES

8+ 10+ 50+ 100=

About a third of the
North American cannabis market
With nearly 40 million residents and more than a million medical
marijuana patients, California’s market represents about a third of the
North American cannabis market.

Estimated Sales in California alone:

$3.7 billion by the end of 2018
$5.1 billion by 2019
$25 billion by 2026

$3.7 Billion $5.1 Billion $25 Billion $50 Billion

According to Arcview Market Research and BDS and Cowen & Co. analytics new report and Business Insider. 7
CALIFORNIA / OIL PRODUCTION
The Company’s California oil production facility is able to produce up to 200 lbs of oil per day, while remaining compliant to all state regulations.

• The California facility has won over 25 gold medals in competition

for best CO2, Best Topical, Best Product, Best Concentrate, Best
Cartridge and Highest Terpene.

• Facility can produce up to 200 lbs of tested cannabis oil per day.

• Processing 2000 lbs of trim per day

• Strategically located for cost effective state-wide distribution

• High quality oils servicing brands such as, Julian

Marley Juju Royal, California SAP, Jay & Silent Bob

8
CALIFORNIA / DESERT ZEN
Chemesis is able to provide fully compliant distribution, packaging and transportation services for companies.
PACKAGING
We provide packaging services for
flower, edibles, and extracts with high
grade equipment and suppliers, while
maintaining compliance.
DISTRIBUTION &
TRANSPORTATION
Network of cultivators, manufacturers,
extractors, and retailers that have
proven their success.
Partnerships with over 650
dispensaries around the state
COMPLIANCE
Maintaining compliance is our top
priority, from packaging to distribution
we maintain open communication
with regulators to ensure we maintain
compliance at all levels.
9
CALIFORNIA / JAY & SILENT BOB
Chemesis has an exclusive partnership with Kevin Smith and Jason Mewes • The partnership brings a collective footprint of over 12.4 million followers. With a cult like
to bring the Jay & Silent Bob brand to consumers in the U.S. following, J&SB is proving to be a highly sought after brand.

•Kevin is heavily involved and has a podcast ‘Silent But Deadly’ that holds the #1 Comedy
Album on iTunes.

Jay and Silent Bob have been making movies since 1994 and remain relevant in people’s lives
till this day.

• Clerks - 1994
• Mallrats - 1995
• Chasing Amy - 1997
• Dogma - 1999
• Jay and Silent Bob Strike Back - 2001
• Jay and Silent Bob Do Degrassi - 2005
• Clerks 2 - 2006
• Zack and Miri Make a Porno - 2008

10
CALIFORNIA
California Sap produces the highest quality CO2 extracts. California SAP utilizes an all-natural process with state-of-the-art equipment that has made them a champion in
the CO2 Concentrate categories. California SAP produces finer oils than others because their SAP is not mixed with artificial fillers or additives.

11
QuickStrip™ ORAL THIN STRIPS
Chemesis has an exclusive partnership to produce, distribute, and sell QuickStrip™ products in California, and Puerto Rico.

The innovative Quickstrips allow for safe and

effective oral fast-dissolving delivery system.

RDT proprietary formulation (RDMx mixture), and a first

mover competitive advantage in the global markets
offer extensive immediate and long-term financial
benefits for brands. QuickStrip™ delivery system can
be deployed as a device instead of a drug to limit the
time and cost of bringing new products to market or
extending lines within an existing approved API.

12
CALIFORNIA / VIVERIAN

Viverian all-natural premium supplements feature robust blends of essential vitamins, botanical extracts, adaptogens, and CBD. These specially-formulated capsules and
tinctures deliver the dynamic benefits of high quality hemp-derived CBD and promote everyday health and wellness.

• Target pain and inflammation

• Promote the body’s natural healing power

• Provide mental clarity and may reduce stress

• Allow for a more restful night’s sleep

viverian • Contains no THC

• Not addictive

13
PUERTO RICO / MARKET
“Puerto Rico public health department anticipates
registration of 100,000 registered patients by end of 2019”
(Currently there is over 40,000 patients on the island)

“Legalized medical cannabis for qualifying health conditions

in 2015, allows the use of medical cannabis derivatives”

“Health Conditions include HIV, cancer, multiple scleosis,

migraines, anxiety, epilepsy, and other conditions”
Reference: http://www.salud.gov.pr/Documents/Cannabis/

David Quinones, operations director of

Natural Ventures speaks during an interview
in Caguas, Puerto Rico.

(AP Photos / Ricardo Arduengo)

13
PUERTO RICO / PRODUCTS
Chemesis has acquired 80% of Natural Ventures, a Puerto Rico based cannabis company. Chemesis is currently retailing exclusive products in 7+ stores in Puerto Rico.

• Natural Ventures is a seed to sale, medical cannabis company based in

Caguas,Puerto Rico.

• The company has been in operation since early 2017 and is currently expanding
to meet patient demand.

• Natural Ventures is licensed to cultivate 100,000 sqft. of cannabis and also has
35,000 sqft. of manufacturing floor space.

• Natural Ventures uses CO2 based extraction for its oil-based products.

• Natural Ventures services approximately 90% of dispensaries on the island.

14
COLOMBIA / MARKET

“Colombia’s betting on diversification of exports, of its

portfolio and this is one of the most aggressive ways,” said
Rodrigo Arcila, head of the cannabis growers association.
Courtesy of Reuters

COLOMBIA

global cannabis market • Colombia has many free trade agreements, which opens the
door for international expansion.

• Colombia has been declared in the top five most biodiverse

climates.

• An extremely diverse climate allows crop to be harvested year

round, increasing yield and profitability.

• Population of 45 million people.

$8 Billion $40 Billion

global market that could be worth $40 billion a year.

15
COLOMBIA / LA FINCA INTERACTIVA-ARCHNA MED

Chemesis has signed a binding agreement to acquire 100% Colombia based La Finca.

• 1,000 acres of outdoor cultivation

• Partnership with the largest university in Colombia,

Universidad Nacional de Colombia to develop
seed strains that improve the yield of biomass
and flower while shortening crop cycles.

• Partnership with the Universidad Francisco José de Caldas,

focusing on educational aspects of cannabis cultivation.

• Relationships with over 2,000 farming families across Colombia

16
PROJECTIONS
Combined Projections of California, Puerto Rico, and Columbia

Year 5
$132,362,460 $53,785,972 $78,576,488 $15,177,327 $63,381,161

Year 4

$91,329,784 $37,882,484 $53,447,300 $12,850,336 $40,578,963

Year 3

$63,631,651 $26,853,299 $ 36,778,351 $10,960,433 $25,799,919

Year 2

$45,907,833 $19,577,225 $26,330,608 $9,871,607 $16,441,001

$16,543,632 $8,443,578 $6,442,540 $1,983,038

Year 1

$8,100,054

TOTAL COST OF GROSS PROFIT SG&A NET INCOME

REVENUES SALES EXPENSES (BEFORE INTEREST, DEPRECIATION
17
CAP TABLE

Total shares
outstanding Total shares Options
in shell outstanding ($1 Exercise Price)

16,040,076 48,124,684 64,164,760 4,399,472 5,800,000 74,364,232

Vend-In-Shares Warrants Fully Diluted

(36 Month Escrow) ($2 Exercise Price) Issued & Outstanding

18
chemesis.com